Invokana® Lawsuits: SGLT2 Inhibitors Linked to Ketoacidosis

A newer class of drugs used to treat type 2 diabetes (Sodium-glucose cotransporter-2 or SGLT2 inhibitors) may lead to ketoacidosis, a condition which causes dangerously high levels of blood acids that can poison the body.

The Food and Drug Administration (FDA) is currently investigating numerous reports of ketoacidosis in patients taking these drugs. Symptoms of ketoacidosis may include difficulty breathing, nausea, vomiting, abdominal pain, confusion, or unusual fatigue or sleepiness.

Prescribed for lowering an individual’s blood sugar, SGLT2 inhibitors work by prompting the kidneys to remove sugar from the body through urine. The most common SGLT2 inhibitor brands include:

  • Invokana® (Approved March 2013)
  • Farxiga® (Approved January 2014)
  • Jardiance® (Approved August 2014)

Other drugs in the class include Invokamet™, Xigduo XR™ and Glyxambi®, combination type 2 diabetes treatments that include an SGLT2 inhibitor drug as one of its two components.

SGLT2 Inhibitors also Linked to Kidney Injuries

The Institute for Safe Medication Practices (ISMP) stated in May 2015 that the FDA had received 457 adverse event reports for Invokana in a 12 month period since the drug launched. Among the reports, 54 involved kidney failure or renal injury. Additionally, some patient safety advocates feel that other red flags may point to increased risk of heart attack, stroke, kidney cancer, and bladder cancer.

On June 14 2016, the FDA strengthened their existing warning about the risk of acute kidney injuries for this class of drugs. Revised warning labels now include more information about acute kidney injury and added recommendations to minimize this issue.

Were You Diagnosed with Ketoacidosis or Another Serious Health Problem?

If you or a loved one were prescribed Invokana, Jardiance, or Farxiga, and were diagnosed with ketoacidosis, kidney problems, kidney or bladder cancer, or another serious injury, you could be entitled to compensation. Contact Sokolove Law today for a free, confidential legal consultation.

Invokana® Lawsuits: Drug Linked to Increased Risk of Amputations

The Food and Drug Administration (FDA) warns that the type 2 diabetes medicine canagliflozin (Invokana®, Invokamet®, Invokamet® XR) causes an increased risk of leg and foot amputations, based on data from two large clinical trials. As a result, the FDA now requires the makers of the drug to add a “black box” warning to the drug labels to better describe the risk of amputations to patients.

Prescribed for lowering an individual’s blood sugar, Invokana works by prompting the kidneys to remove sugar from the body through urine, and Invokana is one of the most common sodium-glucose co-transporter-2 (SGLT2) inhibitor brands.

Diabetics and Amputations

People with diabetes are typically at a greater risk of needing an amputation procedure, but clinical trials now reveal that the well-known medication Invokana may double the risk. While the reason behind why Invokana increases the chances of amputation is not clearly understood, researchers agree that Invokana, along with other risk factors makes needing an amputation more likely.

Did You Need an Amputation After Taking Invokana?

If you or a loved one took Invokana and later needed an amputation surgery, you could be entitled to compensation. Contact Sokolove Law today for a free, confidential legal consultation.

 

Invokana® is a registered trademark of Janssen Pharmaceuticals, Inc.
Invokamet ™ is a trademark of Janssen Pharmaceuticals, Inc.
Farxiga® is a registered trademark of the AstraZeneca group of companies.
Xigduo XR™ is a trademark of the AstraZeneca group of companies.
Jardiance® and Glyxambi® are registered trademarks of Boehringer Ingelheim Pharmaceuticals, Inc.
Note: Do not change medications without first consulting your doctor.
Invokana®, Invokamet®, Invokamet® XR are registered trademarks of Janssen Pharmaceuticals, Inc. Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation.
Author:Sokolove Law
Sokolove Law

The Sokolove Law Content Team consists of writers and editors who work alongside the firm’s attorneys and case managers. The team strives to present the most accurate and relevant information for those who need legal help.

Last modified: September 20, 2019